Incyte

🇺🇸United States
Ownership
-
Employees
2.5K
Market Cap
$12.6B
Website
Introduction

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials
Related News

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

First Posted Date
2012-06-22
Last Posted Date
2019-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
106
Registration Number
NCT01626573

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase 1
Terminated
Conditions
Melanoma
Interventions
Drug: Epacadostat
Drug: Placebo
Drug: ipilimumab
First Posted Date
2012-05-24
Last Posted Date
2019-03-26
Lead Sponsor
Incyte Corporation
Target Recruit Count
136
Registration Number
NCT01604889

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

First Posted Date
2011-10-04
Last Posted Date
2019-03-27
Lead Sponsor
Incyte Corporation
Target Recruit Count
45
Registration Number
NCT01445769

Study of Ruxolitinib in Pancreatic Cancer Patients

First Posted Date
2011-08-26
Last Posted Date
2018-02-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
136
Registration Number
NCT01423604

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Phase 2
Completed
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Drug: Ruxolitinib
First Posted Date
2011-05-05
Last Posted Date
2020-01-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
66
Registration Number
NCT01348490

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase 2
Completed
Conditions
Myelofibrosis
Interventions
Drug: Ruxolitinib
First Posted Date
2011-04-22
Last Posted Date
2014-03-10
Lead Sponsor
Incyte Corporation
Target Recruit Count
41
Registration Number
NCT01340651

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Phase 1
Completed
Conditions
Myelofibrosis
Interventions
Drug: Ruxolitinib
First Posted Date
2011-03-17
Last Posted Date
2022-03-09
Lead Sponsor
Incyte Corporation
Target Recruit Count
69
Registration Number
NCT01317875

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

First Posted Date
2010-12-06
Last Posted Date
2012-01-25
Lead Sponsor
Incyte Corporation
Target Recruit Count
20
Registration Number
NCT01254136

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

First Posted Date
2010-11-19
Last Posted Date
2019-03-06
Lead Sponsor
Incyte Corporation
Target Recruit Count
222
Registration Number
NCT01243944

A Dose-escalation Study in Subjects With Advanced Malignancies

Phase 1
Completed
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
Drug: INCB024360
First Posted Date
2010-09-06
Last Posted Date
2018-01-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
52
Registration Number
NCT01195311
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy